Regeneron, Sanofi Receive CRL for Add-On Dupilumab sBLA for Chronic Spontaneous Urticaria

The latest indication for the dual inflammatory pathway-targeting biologic expands dupilumab's clinical availability to third chronic skin disease.

Related Keywords

United States ,San Antonio ,Texas ,Berlin ,Germany ,American ,Smitht Dupilumab ,Marcus Maurer ,Drug Administration ,American Academy Of Allergy ,Complete Response Letter ,Biologics License Application ,Itch Severity Score ,Urticaria Activity Score ,Charite Universitatsmedizin Berlin ,American Academy ,Dermatology Life Quality Index ,Published October ,Significantly Reduces Itch ,Patients With Chronic Spontaneous Urticaria ,Results From ,Published February ,Chronic Spontaneous Urticaria Activity ,Chronic Spontaneous Urticaria ,